Investor Relations
17 March 2022(Thursday)
FY2021 Annual Results Announcement Webinar Invitation
Dear Investors and Analysts,
Hua Medicine (2552.HK) cordially invites you or your representative to attend the online webinar in relations to the Company’s FY2021 annual results, which will be held 8:00 AM GMT+8, 17 March 2022 (Thursday).
During the webinar, management will provide a review of the Company’s business and financial performance, as well
as address the questions surrounding the full-year financial results in 2021.
Details of the webinar are as follows:
Language: | English |
Date: | 17 March 2022 (Thursday) |
Time: | Login starts: 7:45AM GMT+8 |
Duration: | Approx. 45 mins (including Q&A session) |
Management: |
Dr. Li Chen, CEO, Founder, and Chief Scientific Officer |
RSVP: | Registration Link:https://icaasia.zoom.us/webinar/register/WN_brRTyTDdQGu5BI0KfeDFSw |
Q&A: |
If you have any questions, please send them to huamedicine@icaasia.com before 16 March 2022 (Wednesday). |
*If you are intended to attend the Chinese session (9:00AM GMT+8, 17 March), please send an email to huamedicine@icaasia.com for registration. Meeting details will be provided upon confirmation.
About Hua Medicine
Hua Medicine is an innovative drug development company in China focused on developing novel therapies forpatients worldwide with unmet medical needs. Hua Medicine teams up with global high caliber people and integratesultimate global resources to explore breakthrough technologies and products, and accelerate global innovation indiabetes care. Targeted on glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug, restoring glucosesensitivity in T2D patients, has completed SEED and DAWN registration trials and filed NDA in China. This global firstin-class glucokinase activator (GKA) has demonstrated its potential of achieving diabetes remission to help millions ofdiabetic patients around world.
滬ICP備14036654號(hào)-1
滬公網(wǎng)安備 31011502013809號(hào) Privacy Statement Terms of Use
